Hormonal signaling and pituitary adenomas

Neuroendocrinology

Volumn 85, Issue 2, 2007, Pages 101-109

  Spada, Anna ^a   Lania, Andrea ^a   Mantovani, Giovanna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

G protein; GNAS1 mutation; Hypothalamic neurohormones; Pituitary adenomas

Indexed keywords

CYCLIC AMP; GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HORMONE RECEPTOR; NEUROHORMONE;

CARCINOGENESIS; CELL DIVISION; CONFERENCE PAPER; DISEASE ASSOCIATION; FEEDBACK SYSTEM; GENE MUTATION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOMA; FEEDBACK; HORMONES; HUMANS; HYPOTHALAMIC HORMONES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; PITUITARY NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 34248231793     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100440     Document Type: Conference Paper

References (66)

1. Farrel WE, Clayton RN: Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol 2000;21:174-198.
2. Asa SL, Ezzat S: The pathogenesis of pituitary tumours. Nat Rev Cancer 2002;2:836-849.
3. Korbonits M, Morris DG, Nanzer A, Kola B, Grossman AB: Role of regulatory factors in pituitary tumour formation. Front Horm Res 2004;32:63-95.
4. Heaney AP, Melmed S: Molecular targets in pituitary tumours. Nat Rev Cancer 2004;4:285-295.
5. Lania AG, Mantovani G, Spada A: Mechanisms of disease: mutations of G proteins and protein-coupled receptors in endocrine diseases. Nat Clin Pract Endocrinol Metab 2006;2:681-693.
6. Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A, Klibanski A: Clinically nonfunctioning pituitary adenomas are monoclonal in origin. J Clin Invest 1990;86:336-340.
7. Burrow GN, Wortzman G, Rewcastle NB, Hodgate RC, Kovacs K: Microadenomas of the pituitary and abnormal sella tomograms in an unselected autopsy series. N Engl J Med 1981;304:156-158.
8. Elster AD: Modern imaging of the pituitary. Radiology 1993;187:1-14.
9. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL: Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 1992;74:914-919.
10. Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D: H-ras mutations in human pituitary carcinoma metastasis. J Clin Endocrinol Metab 1994;78:842-846.
11. Simpson DJ, Magnay J, Bicknell JE, Barkan AL, McNicol AM, Clayton RN, Farrel WE: Chromosome 13q deletion mapping in pituitary tumors: Infrequent loss of the retinoblastoma susceptibility gene (RB1) despite loss of RB1 product in somatotropinomas. Cancer Res 1999;59:1562-1566.
12. Levy A, Hall L, Yeudall WA, Lightman SL: p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol 1994;41:809-814.
13. Asa S, Kovacs K, Stefaneanu L, Horvath E, Billestrup N, Gonzales-Manchon C, Vale W: Pituitary adenomas in mice transgenic for growth hormone-releasing hormone. Endocrinology 1992;131:2083-2089.
14. Thapar K, Kovacs K, Stefaneau L, Scheithauer B, Killinger DW, Lloyd RV, Smyth HS, Barr A, Thorner MO, Gaylinn B, Laws ER Jr: Overexpression of the growth-hormone-releasing hormone gene in acromegaly associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. Am J Pathol 1997;151:769-784.
15. Lee EJ, Kotlar TJ, Ciric I, Lee MK, Lim SK, Lee HC, Huh KB, Mayo KE, Jameson JL: Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors. J Clin Endocrinol Metab 2001;86:3989-3995.
16. Yamada M, Hashimoto K, Satoh T, Shibusawa N, Kohga H, Ozawa Y, Yamada S, Mori M: A novel transcript for the thyrotropin-releasing hormone receptor in human pituitary and pituitary tumors. J Clin Endocrinol Metab 1997;82:4224-4228.
17. 2+ levels and adenylyl cyclase activity in human nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1991;71:913-918.
18. De Keyzer Y, Rene P, Beldjord C, Lenne F, Bertagna X: Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clin Endocrinol (Oxf) 1998;49:475-482.
19. Barlier A, Zamora AJ, Grino M, Gunz G, Pellegrini-Bouiller I, Morange-Ramos I, Figarella-Branger D, Dufour H, Jaquet P, Enjalbert A: Expression of functional growth hormone secretagogue receptors in human pituitary adenomas. Polymerase chain reaction, triple in-situ hybridization and cell culture studies. J Neuroendocrinol 1999;11:491-502.
20. Scanlon MF, Rodriguez-Arnao MD, McGregor AM, Weightman D, Lewis M, Cook DB, Gomez-Pan A, Hall R: Altered dopaminergic regulation of thyrotropin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. Clin Endocrinol 1981;14:133-149.
21. Barkan AL: Acromegaly. Trends Endocrinol Metab 1992;6:205-210.
22. Asa SL, Kelly MA, Grandy DK, Low MJ: Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology 1999;140:5348-5355.
23. Friedman E, Adams EF, Hoog A, Gejman PV, Carson E, Larsson C, De Marco L, Werner S, Fahlbusch R, Nordenskjold M: Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab 1994;78:568-574.
24. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A: Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994;60:314-322.
25. Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A: Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somato statin analog treatment. J Clin Endocrinol Metab 2001;86:3809-3814.
26. Filopanti F, Ronchi C, Ballare E, Bondioni S, Lania AG, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A: Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 2005;90:4824-4828.
27. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH: Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000;85:781-792.
28. Vallar L, Spada A, Giannattasio G: Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987;330:566-567.
29. Landis C, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L: GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989;340:692-696.
30. Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M, Fahlbusch R: Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery 1993;33:198-200.
31. Yang I, Park S, Ryu M, Woo J, Kim S, Kim J, Kim Y, Choi Y: Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol 1996;134:720-726.
32. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, Enjalbert A, Bonthron DT: Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001;107:R31-R36.
33. Mantovani G, Bondioni S, Lania AG, Corbetta S, de Sanctis L, Cappa M, Di Battista E, Chanson P, Beck-Peccoz P, Spada A: Parental origin of Gsα mutations in the McCune-Albright syndrome and in isolated endocrine tumors. J Clin Endocrinol Metab 2004;89:3007-3009.
34. Williamson EA, Daniels M, Foster S, Kelly WF, Kendall-Taylor P, Harris PE: Gsα and Giα mutations in clinically non-functioning pituitary tumours. Clin Endocrinol 1994;41:815-820.
35. Petersenn S, Heyens M, Ludecke DK, Beil FU, Schulte HM: Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas. Clin Endocrinol (Oxf) 2000;52:35-42.
36. Ballarè E, Mantovani S, Bassetti M, Lania A, Spada A: Immunodetection of G proteins in human pituitary adenomas: evidence for a low expression of proteins of the Gi subfamily. Eur J Endocrinol 1997;137:482-489.
37. Alvaro V, Levy L, Dubray C, Roche A, Peillon F, Querat B, Joubert D: Invasive human pituitary tumors express a point-mutated α-protein kinase C. J Clin Endocrinol Metab 1993;77:1125-1129.
38. Esapa CT, Harris PE: Mutation analysis of protein kinase A catalytic subunit in thyroid adenomas and pituitary tumours. Eur J Endocrinol 1999;141:409-412.
39. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA: Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
40. Kaltsas GA, Kola B, Borboli N, Morris DG, Gueorguiev M, Swords FM, Czirjak S, Kirschner LS, Stratakis CA, Korbonits M, Grossman AB: Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin Endocrinol (Oxf) 2002;57:443-448.
41. Lania AG, Mantovani G, Ferrero S, Pellegrini C, Bondioni S, Peverelli E, Braidotti P, Locatelli M, Zavanone ML, Ferrante E, Bosari S, Beck-Peccoz P, Spada A: Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res 2004;64:9193-9198.
42. Otsuka E, Tamiya T, Yamauchi T, Ogura T, Ohmoto T, Makino M: Quantitative analysis of growth-related factors in human pituitary adenomas - lowered insulin-like growth factor-I and its receptor mRNA in growth hormone-producing adenomas. Regul Pept 1999;63:31-38.
43. McAndrew J, Paterson AJ, Asa SL, McCarthy KJ, Kudlow JE: Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology 1995;136:4479-4488.
44. LeRiche V, Asa S, Ezzat S: Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J Clin Endocrinol Metab 1996;81:656-662.
45. Ezzat S, Smyth HS, Ramyar L, Asa S: Heterogeneous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. J Clin Endocrinol Metab 1995;80:878-884.
46. Gonsky R, Herman V, Melmed S, Fagin J: Transforming DNA sequences present in human prolactin-secreting pituitary tumors. Mol Endocrinol 1991;5:1687-1695.
47. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL: Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002;109:69-74.
48. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G: N-CAM modulates tumourcell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 2001;3:650-657.
49. Elias KA, Weiner RI: Direct arterial vascularization of estrogen induced prolactin-secreting anterior pituitary tumor. Proc Natl Acad Sci USA 1984;81:4549-4553.
50. Danila DC, Inder WJ, Zhang X, Alexander JM, Swearingen B, Hedley-Whyte ET, Klibanski A: Activin effects on neoplastic proliferation of human pituitary tumors. J Clin Endocrinol Metab 2000;85:1009-1015.
51. Wessels HT, Hofland LJ, van der Wal R, van Gastel L, van Koetsveld PM, de Herder WW, de Jong FH: In vitro secretion of FSH by cultured clinically nonfunctioning and gonadotroph pituitary adenomas is directly correlated with locally produced levels of activin A. Clin Endocrinol (Oxf) 2001;54:485-492.
52. Zhou Y, Sun H, Danila DC, Johnson SR, Sigai DP, Xun Zhang X, Klibanski A: Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling. Mol Endocrinol 2000;14:2066-2075.
53. Marinissen MJ, Gutkind JS: G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001;22:368-376.
54. Naor Z, Benard O, Seger R: Activation of MAPK cascades by G-protein-coupled receptors: the case of gonadotropin-releasing hormone receptor. Trends Endocrinol Metab 2000;11:91-99.
55. Lania A, Filopanti M, Corbetta S, Losa M, Ballare E, Beck-Peccoz P, Spada A: Effects of hypothalamic neuropeptides on extracellular signal-regulated kinase (ERK1 and ERK2) cascade in human tumoral pituitary cells. J Clin Endocrinol Metab 2003;88:1692-1696.
56. Mantovani G, Bondioni S, Ferrero S, Gamba B, Ferrante E, Peverelli E, Corbetta S, Locatelli M, Rampini P, Beck-Peccoz P, Spada A, Lania AG: Effect of cyclic adenosine 3′,5′-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2005;90:6721-6724.
57. Stork PJ, Schmitt JM Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002;12:258-266.
58. Kolch W: Coordinating ERK/MAPK signalling through scaffolds and inhibitors Nat Rev Mol Cell Biol 2005;6:827-838.
59. Dickie MM, Wolley GW: Spontaneous basophilic tumor of the pituitary gland in gonadectomized mice. Cancer Res 1949;16:372-384.
60. Furth J, Dent NN, Burnett WT: The mechanism of induction and the characteristics of pituitary tumors induced by thyroidectomy. J Clin Endocrinol Metab 1955;15:81-87.
61. Snyder PJ: Gonadotropin cell adenomas of the pituitary. Endocr Rev 1985;6:552-564.
62. Beck Peccoz P, Brucker-Davis F, Persani L, Smallidge RC, Weintraub BD: Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610-638.
63. Karl M, Lamberts SW, Koper JW, Katz DA, Huizenga NE, Kino T, Haddad BR, Hughes MR: Chrousos GP. Cushing's disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominantnegative glucocorticoid receptor mutation. Proc Assoc Am Physicians 1996;108:296-307.
64. Huizenga NA, de Lange P, Koper JW, Clayton RN, Farrell WE, van der Lely AJ, Brinkmann AO, de Jong FH, Lamberts SW: Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. J Clin Endocrinol Metab 1998;83:917-921.
65. Ando S, Sarlis NJ, Oldfield EH, Yen PM: Somatic mutation of TRβ can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 2001;86:5572-5576.
66. Phillips SA, Rotman-Pikielny P, Lazar J, Ando S, Hauser P, Skarulis MC, Brucker-Davis F, Yen PM: Extreme thyroid hormone resistance in a patient with a novel truncated TR mutant. J Clin Endocrinol Metab 2001;86:5142-5147.